Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in North Carolina: - Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
- Wayne Memorial Hospital — Goldsboro, North Carolina
- Onslow Memorial Hospital — Jacksonville, North Carolina
- Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- Cone Health Cancer Center — Greensboro, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in North Carolina: - Levine Cancer Institute/ Atrium Health — Charlotte, North Carolina
- Duke Cancer Institute — Durham, North Carolina
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
- Comprehensive Cancer Center of Wake Forest* — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in North Carolina: - East Carolina University — Greenville, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in North Carolina: - Duke University — Durham, North Carolina
- Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in North Carolina: - Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in North Carolina: - Duke University School of Medicine — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in North Carolina: - Levine Children's Hospital- Pediatric Neuro-Oncology — Charlotte, North Carolina
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Network
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in North Carolina: - Duke Cancer Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in North Carolina: - Duke Cancer Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in North Carolina: - Duke University Health System — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard …
Sponsor: Cedars-Sinai Medical Center
NCT ID: NCT05708352
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Sponsor: Duke University
NCT ID: NCT06069726
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the su…
Sponsor: Darell Bigner
NCT ID: NCT06177964
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT05692635
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina